Literature DB >> 27139462

Non-contrast cardiac CT immediately after percutaneous coronary intervention: does it predict the risk of left ventricular remodeling in patients with ST-elevation myocardial infarction?

Khulan Khurelsukh1, Yun-Hyeon Kim2, Hyun Ju Seon1, Jang Hyun Song1, Seo Yeon Park1, Sung Min Moon1, Soo Hyun Kim1, Doo Sun Sim3, Youngkeun Ahn3.   

Abstract

To assess the clinical utility of non-contrast cardiac CT (CCT) immediately after successful percutaneous coronary intervention (PCI) for predicting the risk of left ventricle (LV) remodeling in the management of patients with acute myocardial infarction (AMI), 35 patients with AMI underwent non-contrast CCT immediately after PCI. Volume and transmural extent of myocardial delayed enhancement (DE) were assessed on non-contrast CCT. Serial echocardiography and serologic biomarkers were evaluated at baseline and at 2 and 12 months after AMI. Based on an increase in left ventricular end-diastolic volume (LVEDV) ≥20 % at 2 months, patients were classified into two groups: LV remodeling (group 1, n = 14) and no LV remodeling (group 2, n = 21). Clinical characteristics, imaging parameters, and serologic biomarkers were compared between the two groups. Higher incidence of hypertension, longer time to reperfusion, and higher Killip classification at admission were observed for group 1 than for group 2, but these differences were not statistically significant (P > 0.05). Greater volume and transmural extent of DE on non-contrast CCT and poorer resolution of ST-segment elevation on ECG were observed in group 1 compared to group 2, but these results were not statistically significant (P > 0.05). Measurement of biochemical markers showed that probrain natriuretic peptide (proBNP), initial high sensitivity C reactive protein (hs-CRP), and maximum troponin T level were significantly higher in group 1 than in group 2 (P < 0.05) at 2 months. Based on the trend of greater volume and transmural extent of DE in group 1 compared to group 2, non-contrast CCT immediately after PCI, in combination with serologic biomarkers (proBNP, hs-CRP, and troponin T) might be useful for managing patients with AMI.

Entities:  

Keywords:  Acute myocardial infarction; Left ventricular remodeling; Non-contrast cardiac CT; Primary percutaneous coronary intervention

Mesh:

Substances:

Year:  2016        PMID: 27139462     DOI: 10.1007/s10554-016-0900-6

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  37 in total

1.  Quantitative troponin and death, cardiogenic shock, cardiac arrest and new heart failure in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS): insights from the Global Registry of Acute Coronary Events.

Authors:  Sanjit S Jolly; Heather Shenkman; David Brieger; Keith A Fox; Andrew T Yan; Kim A Eagle; P Gabriel Steg; Ki-Dong Lim; Ann Quill; Shaun G Goodman
Journal:  Heart       Date:  2010-11-12       Impact factor: 5.994

2.  Contrast-enhanced multidetector computed tomography viability imaging after myocardial infarction: characterization of myocyte death, microvascular obstruction, and chronic scar.

Authors:  Albert C Lardo; Marco A S Cordeiro; Caterina Silva; Luciano C Amado; Richard T George; Anastasios P Saliaris; Karl H Schuleri; Veronica R Fernandes; Menekhem Zviman; Saman Nazarian; Henry R Halperin; Katherine C Wu; Joshua M Hare; Joao A C Lima
Journal:  Circulation       Date:  2006-01-24       Impact factor: 29.690

3.  Prognostic value of myocardial contrast delayed enhancement with 64-slice multidetector computed tomography after acute myocardial infarction.

Authors:  Akira Sato; Toshihiro Nozato; Hiroyuki Hikita; Daiki Akiyama; Hidetaka Nishina; Tomoya Hoshi; Hideaki Aihara; Yuki Kakefuda; Hiroaki Watabe; Michiaki Hiroe; Kazutaka Aonuma
Journal:  J Am Coll Cardiol       Date:  2012-02-21       Impact factor: 24.094

4.  Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18.

Authors:  David A Morrow; James A de Lemos; Marc S Sabatine; Sabina A Murphy; Laura A Demopoulos; Peter M DiBattiste; Carolyn H McCabe; C Michael Gibson; Christopher P Cannon; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2003-04-16       Impact factor: 24.094

5.  Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction.

Authors:  N Nagaya; T Nishikimi; Y Goto; Y Miyao; Y Kobayashi; I Morii; S Daikoku; T Matsumoto; S Miyazaki; H Matsuoka; S Takishita; K Kangawa; H Matsuo; H Nonogi
Journal:  Am Heart J       Date:  1998-01       Impact factor: 4.749

Review 6.  The B-type natriuretic peptide assay: a rapid test for heart failure.

Authors:  W Frank Peacock
Journal:  Cleve Clin J Med       Date:  2002-03       Impact factor: 2.321

7.  Brain natriuretic peptide and other cardiac markers predicting left ventricular remodeling and function two years after myocardial infarction.

Authors:  Regina Grybauskiene; Dovile Karciauskaite; Julija Brazdzionyte; Jūrate Janenaite; Zita Bertasiene; Pranas Grybauskas
Journal:  Medicina (Kaunas)       Date:  2007       Impact factor: 2.430

8.  C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction.

Authors:  Stein Ørn; Cord Manhenke; Thor Ueland; Jan K Damås; Tom Eirik Mollnes; Thor Edvardsen; Pål Aukrust; Kenneth Dickstein
Journal:  Eur Heart J       Date:  2009-03-19       Impact factor: 29.983

Review 9.  Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.

Authors:  J N Cohn; R Ferrari; N Sharpe
Journal:  J Am Coll Cardiol       Date:  2000-03-01       Impact factor: 24.094

Review 10.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

Authors:  Ellen C Keeley; Judith A Boura; Cindy L Grines
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.